Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xilio Therapeutics (XLO) Gains from Investment Securities (2024 - 2025)

Xilio Therapeutics (XLO) has disclosed Gains from Investment Securities for 2 consecutive years, with -$21.3 million as the latest value for Q4 2025.

  • Quarterly Gains from Investment Securities changed N/A to -$21.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $11.5 million through Sep 2025, up 43.8% year-over-year, with the annual reading at $2.8 million for FY2025, 368.03% up from the prior year.
  • Gains from Investment Securities hit -$21.3 million in Q4 2025 for Xilio Therapeutics, down from $11.5 million in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $11.5 million in Q3 2025 to a low of -$21.3 million in Q4 2025.